Clinical Trials for Teens!
Clinical Research Study for Teens and other Adolescents with Hidradenitis Suppurativa
This is a research study evaluating the safety of an investigational drug as well as how it is processed in the body.
- Age: 9-17
- Severity: moderate to severe
- Location: US
Clinical Trial Spotlight
Clinical study for HS patients
Hidradenitis Suppurativa causes painful symptoms. You can help yourself and others with our clinical study.
- Test our active investigational ingredient
- Supervision by specialised staff
- Study participants wanted!
- Avoid secondary damage from HS
The study is recruiting for the following countries:
- Canada
- United Kingdom
- Netherlands
- Spain
- Poland
- Germany
Looking for Clinical Trials in the U.S.?
Explore current clinical trial opportunities available across the United States. These studies may offer access to new treatments and additional care options.
Open to Exploring Options Beyond the U.S.?
Browse international clinical trials to discover opportunities happening around the world. Expanding your search may open the door to additional possibilities.
US Clinical Trial Opportunities
SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
AGE: 18+
Moderate to Severe
Status: Recruiting
A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
AGE: 12+
Moderate to Severe
Status: Recruiting
A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
AGE: 18+
ALL
Status: Recruiting
Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa
AGE: 18+
Moderate to Severe
Status: Recruiting
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense (TibuSHIELD)
AGE: 18+
II & III
Status: Recruiting
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
AGE: 18+
Moderate to Severe
Status: Recruiting
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
AGE: 12 -17
Moderate to Severe
Status: Recruiting
An Open-label, Time-lagged, Dose-escalation Study to Evalaute the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.
AGE: 18+
Moderate to Severe
Status: Recruiting
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
AGE: 18+
Moderate to Severe
Status: Recruiting
A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa
AGE: 18+
All
Status: Recruiting
Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients.
AGE: 18+
Moderate to Severe
Status: Recruiting
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
AGE: 18+
Moderate to Severe
Status: Recruiting
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
AGE: 12+
I & II
Status: Recruiting
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
AGE: 12+
I & II
Status: Recruiting
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
AGE: 9 to 17
Moderate to Severe
Status: Recruiting
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
AGE: 12+
I, II, III
Status: Recruiting
Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa
AGE: 12+
Moderate to Severe
Status: Recruiting
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
AGE: 18-75
SEVERITY: Moderate to severe
Status: Recruiting
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
AGE: AGE: 18+
SEVERITY: Moderate to severe
Status: Recruiting
A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS) (CEDAR)
AGE: AGE: 18-80
SEVERITY: Moderate or severe
Status: Recruiting
Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%
AGE: AGE: 18+
SEVERITY: Mild to moderate
Status: Recruiting
Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa
AGE: AGE: 18+
HURLEY STAGE: All
Status: CURRENTLY RECRUITING
Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa
AGE: AGE: 18-70
HURLEY STAGE: II & III
Status: CURRENTLY RECRUITING
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
AGE: AGE: 12+
HURLEY STAGE: I & II
Status: CURRENTLY RECRUITING
A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients with Moderate to Severe Hidradenitis Suppurativa
AGE: AGE: 18+
HURLEY STAGE: II & III
Status: CURRENTLY RECRUITING
Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
AGE: AGE: 18+
HURLEY STAGE: II & III
Status: CURRENTLY RECRUITING
Myriad™ Augmented Soft Tissue Reconstruction Registry
AGE: AGE: 18+
HURLEY STAGE: All
Status: CURRENTLY RECRUITING
Regulation of Inflammatory Genes in Hidradenitis Suppurativa
AGE: AGE: 18+
HURLEY STAGE: All
Status: CURRENTLY RECRUITING
A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
AGE: AGE: 18+
HURLEY STAGE: II & III
Status: CURRENTLY RECRUITING
The Living With a Long-Term Condition Study
AGE: AGE: 18+
HURLEY STAGE: All
Status: CURRENTLY RECRUITING
Clinical and Biological Characteristics of Hidradenitis Suppurativa
AGE: AGE: 13+
HURLEY STAGE: All
Status: CURRENTLY RECRUITING
Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) in Routine Clinical Practice in the Russian Federation
AGE: AGE: 18+
SEVERITY: Moderate to Severe
Status: CURRENTLY RECRUITING
Botulinum Toxin Therapy in Hidradenitis Suppurativa
AGE: AGE: 18+
HURLEY STAGE: All
Status: CURRENTLY RECRUITING
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
AGE: AGE: 12+
HURLEY STAGE: II & III
Status: CURRENTLY RECRUITING
A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
AGE: AGE: 18-70
HURLEY STAGE: II & III
Status: CURRENTLY RECRUITING
A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
AGE: AGE: 18-70
HURLEY STAGE: II & III
Status: CURRENTLY RECRUITING
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
AGE: AGE: 18+
HURLEY STAGE: All
Status: CURRENTLY RECRUITING
Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa.
AGE: AGE: 18+
SEVERITY: Moderate to Severe
Status: CURRENTLY RECRUITING
Patient’s Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation
AGE: AGE: 18+
HURLEY STAGE: All
Status: CURRENTLY RECRUITING
Battlefield Acupuncture for Pain in Hidradenitis Suppurativa
AGE: AGE: 18+
HURLEY STAGE: All
Status: CURRENTLY RECRUITING
The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.
AGE: AGE: 18+
HURLEY STAGE: All
Status: CURRENTLY RECRUITING
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
AGE: AGES: 16+
HURLEY STAGE: II & III
Status: CURRENTLY RECRUITING
The Ohio State University Dermatology Biorepository
AGE: AGE: 7+
HURLEY STAGE: All
Status: CURRENTLY RECRUITING
International Clinical Trial Opportunities
SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
AGE: 18+
Moderate to Severe
Status: Recruiting
A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
AGE: 12+
Moderate to Severe
Status: Recruiting
Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa
AGE: 18+
Moderate to Severe
Status: Recruiting
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense (TibuSHIELD)
AGE: 18+
II & III
Status: Recruiting
Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients.
AGE: 18+
Moderate to Severe
Status: Recruiting
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
AGE: 18+
Moderate to Severe
Status: Recruiting
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
AGE: 12+
I & II
Status: Recruiting
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
AGE: 12+
I & II
Status: Recruiting
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
AGE: 9 to 17
Moderate to Severe
Status: Recruiting
Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa
AGE: 12+
Moderate to Severe
Status: Recruiting
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
AGE: AGE: 18+
SEVERITY: Moderate to severe
Status: Recruiting
Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) in Routine Clinical Practice in the Russian Federation
AGE: AGE: 18+
SEVERITY: Moderate to Severe
Status: CURRENTLY RECRUITING
The Living With a Long-Term Condition Study
AGE: AGE: 18+
HURLEY STAGE: All
Status: CURRENTLY RECRUITING
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
AGE: AGE: 12+
HURLEY STAGE: II & III
Status: CURRENTLY RECRUITING
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
AGE: AGES: 16+
HURLEY STAGE: II & III
Status: CURRENTLY RECRUITING
The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.
AGE: AGE: 18+
HURLEY STAGE: All
Status: CURRENTLY RECRUITING
Patient’s Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation
AGE: AGE: 18+
HURLEY STAGE: All
Status: CURRENTLY RECRUITING
Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa.
AGE: AGE: 18+
SEVERITY: Moderate to Severe
Status: CURRENTLY RECRUITING
A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
AGE: AGE: 18-70
HURLEY STAGE: II & III
Status: CURRENTLY RECRUITING